Rituximab in Refractory Myasthenia Gravis - Challenges and Lessons Learnt

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Generalized myasthenia gravis (MG) affects 10%-15% of patients with refractory disease, necessitating novel immunotherapies.
• Rituximab, an immunomodulatory B-cell depleting agent, is an emerging therapeutic option for refractory MG.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab in patients with refractory generalized myasthenia gravis.
• To assess treatment response and steroid dose reduction in a cohort of refractory MG patients treated with rituximab.

Main Methods:

• Retrospective analysis of 12 patients with refractory MG treated with rituximab over 4 years.
• Data collected included patient demographics, serological status, prior treatments (thymectomy), disease severity (crises), treatment response, and adverse events.

Main Results:

• Seven out of eleven (63.6%) autoimmune refractory MG patients showed sustained improvement at 12 months, with a median reduction in steroid dosage.
• Four patients worsened during therapy, including one fatality due to sepsis following prolonged ventilation.
• One patient initially unresponsive to rituximab was diagnosed with congenital myasthenic syndrome.

Conclusions:

• Rituximab appears to be an effective treatment for a significant proportion of patients with refractory generalized myasthenia gravis.
• Further research is warranted to optimize rituximab use and identify predictors of response in refractory MG.